Tariffs Benefit, CFO Exit: What's Going On With Zimmer Biomet Stock On Tuesday?

Zimmer Biomet reported first-quarter adjusted EPS of $2.09, up 15.5% year over year and ahead of the Street estimate of $1.86. The earnings beat suggests solid operating performance and favorable fundamentals for the medical device maker. This is a company-specific positive that could modestly support the stock.

Analysis

Zimmer Biomet reported first-quarter adjusted EPS of $2.09, up 15.5% year over year and ahead of the Street estimate of $1.86. The earnings beat suggests solid operating performance and favorable fundamentals for the medical device maker. This is a company-specific positive that could modestly support the stock.